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Crotalus atrox venom 
preconditioning increases 
plasma fibrinogen and reduces 
perioperative hemorrhage in a rat 
model of surgical brain injury
Cherine H. Kim1, Devin W. McBride1, Ronak Raval2, Prativa Sherchan1, Karen L. Hay2, 
Eric C. K. Gren3, Wayne Kelln3, Tim Lekic1,4, William K. Hayes3, Brian S. Bull5, 
Richard Applegate II2, Jiping Tang1 & John H. Zhang1,2,6
Perioperative bleeding is a potentially devastating complication in neurosurgical patients, and plasma 
fibrinogen concentration has been identified as a potential modifiable risk factor for perioperative 
bleeding. The aim of this study was to evaluate preconditioning with Crotalus atrox venom (Cv-PC) as 
potential preventive therapy for reducing perioperative hemorrhage in the rodent model of surgical 
brain injury (SBI). C. atrox venom contains snake venom metalloproteinases that cleave fibrinogen into 
fibrin split products without inducing clotting. Separately, fibrinogen split products induce fibrinogen 
production, thereby elevating plasma fibrinogen levels. Thus, the hypothesis was that preconditioning 
with C. atrox venom will produce fibrinogen spilt products, thereby upregulating fibrinogen levels, 
ultimately improving perioperative hemostasis during SBI. We observed that Cv-PC SBI animals had 
significantly reduced intraoperative hemorrhage and postoperative hematoma volumes compared 
to those of vehicle preconditioned SBI animals. Cv-PC animals were also found to have higher levels 
of plasma fibrinogen at the time of surgery, with unchanged prothrombin time. Cv-PC studies with 
fractions of C. atrox venom suggest that snake venom metalloproteinases are largely responsible for 
the improved hemostasis by Cv-PC. Our findings indicate that Cv-PC increases plasma fibrinogen levels 
and may provide a promising therapy for reducing perioperative hemorrhage in elective surgeries.
Perioperative bleeding is a serious complication in patients undergoing neurosurgical procedures1,2. 
Intraoperative hemorrhage lengthens and complicates surgery and may trigger further injury by tissue 
hypo-perfusion or disruption of the blood-brain barrier1,3. Postoperative hemorrhage poses a significant threat, 
given the finite nature of the intracranial space. Even small hematomas may result in increased intracranial pres-
sure and brain herniation. Thus, the optimization of perioperative hemostasis in neurosurgical patients is of 
paramount importance.
The surgical brain injury (SBI) rodent model has been established to mimic injury during brain resection4,5. 
Given the elective nature of most neurosurgical procedures, the SBI model is an ideal platform for precondi-
tioning modalities, which are preemptive therapies in which mildly harmful stimuli are administered to induce 
endogenous protective mechanisms prior to major injury. Preconditioning has shown to be protective in the SBI 
model6,7, as well as in many other injury models8–13.
1Department of Physiology & Pharmacology, Loma Linda University School of Medicine, 11175 Campus St, Loma 
Linda, CA 92350, USA. 2Department of Anesthesiology, Loma Linda University School of Medicine, 11175 Campus 
St, Loma Linda, CA 92350, USA. 3Department of Earth and Biological Sciences, Loma Linda University School of 
Medicine, 11175 Campus St, Loma Linda, CA 92350, USA. 4Department of Neurology, Loma Linda University School 
of Medicine, 11175 Campus St, Loma Linda, CA 92350, USA. 5Department of Pathology and Human Anatomy, 
Loma Linda University School of Medicine, Loma Linda, California, USA. 6Department of Neurosurgery Loma Linda 
University School of Medicine, 11175 Campus St, Loma Linda, CA 92350, USA. Correspondence and requests for 
materials should be addressed to J.H.Z. (email: jhzhang@llu.edu)
received: 20 September 2016
Accepted: 12 December 2016
Published: 19 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:40821 | DOI: 10.1038/srep40821
Fibrinogen, an acute phase reactant with a half-life of 3.74 days14, is part of the coagulation cascade and 
provides the substrate for fibrin clot formation. During coagulation, thrombin cleaves fibrinogen, producing 
soluble fibrin monomers that are able to be cross-linked by factor VIIIa to form a network on which a clot is built; 
fibrinogen also plays a role in platelet aggregation15. Decreased plasma fibrinogen levels have been identified 
as a potential modifiable risk factor for perioperative bleeding in cardiothoracic and orthopedic surgeries16–19. 
Lower perioperative fibrinogen levels, even within the normal reference range, have been shown to be associ-
ated with an increased risk of postoperative bleeding complications in patients undergoing elective intracra-
nial surgery20,21. In current practice, the options for increasing plasma fibrinogen are limited to transfusions of 
fibrinogen-containing preparations, such as fresh frozen plasma, cryoprecipitate, and fibrinogen concentrate. 
The concentrations of fibrinogen in these preparations vary and large volumes of fresh frozen plasma are often 
necessary to increase plasma fibrinogen, making fluid overload an important consideration in fibrinogen sup-
plementation. Furthermore, these transfusions are not without risk; they are associated with complications that 
include allergic reaction, infections, and transfusion-related acute lung injury22,23.
The hemostatic properties of snake venom toxins have long been studied for potential uses in clinical medi-
cine. Some are used to detect coagulation disorders in the medical laboratory, while others have been examined 
for treating patients with coagulopathies24,25. Crotalus atrox venom contains snake venom metalloproteinases 
that cleave fibrinogen into fibrin split products in such a way that renders the proteins useless in fibrin polym-
erization26,27. Fibrin split products have been previously shown to increase fibrinogen plasma levels by inducing 
endogenous production of fibrinogen in hepatocytes28–30. The unique degradation of fibrinogen by C. atrox snake 
venom metalloproteinases —creating fibrin split products without the induction of clotting—presents an oppor-
tunity to harness the toxic nature of the venom to elicit an endogenous response to increase plasma fibrinogen 
levels prior to elective surgery. We hypothesize that C. atrox venom preconditioning (Cv-PC) prior to surgery will 
increase plasma fibrinogen, thereby decreasing perioperative bleeding in the rodent surgical brain injury model.
Results
Cv-PC Reduces Intraoperative Blood Loss In Vivo. SBI resulted in an intraoperative hemorrhage vol-
ume of 1475 ± 75 μ L which was significantly higher than that observed in sham animals (188 ± 23 μ L). Twenty-
four hours after Cv-PC, a dose-dependent reduction of intraoperative hemorrhage by 17.2% to 35.0% was 
Figure 1. Crotalus atrox venom preconditioning (Cv-PC) reduces intraoperative hemorrhage and 
postoperative hematoma in a dose-dependent manner in SBI. (A) Schematic timeline of treatments and 
outcomes; treatment group rats received three subcutaneous doses of vehicle (normal saline) or Cv-PC (10%, 
20%, and 30% of the LD50 dose) at 72 h, 48 h, 24 h prior to surgery; sham animals received craniotomy only; 
intraoperative hemorrhage volume was collected throughout surgery and postoperative hematoma was 
collected at 24 h post-surgery. (B) Intraoperative hemorrhage and (C) postoperative hematoma volumes were 
assessed by spectrophotometric hemoglobin assay; both were reduced by subcutaneous Cv-PC in a dose-
dependent manner. Cv-PC: Crotalus atrox venom preconditioning; SBI: surgical brain injury. *p < 0.05 vs 
Sham, #p < 0 .05 vs Vehicle. Data are shown as mean ± SEM, n = 5–6 all groups. 1-way ANOVA, with Tukey’s 
comparisons, was used to determine differences.
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observed in Cv-PC animals subjected to SBI: 1221 ± 70 μ L, 991 ± 62 μ L, and 958 ± 75 μ L in the 10%, 20%, and 
30% LD50 (50% of the lethal dose) doses, respectively (Fig. 1B). Cv-PC with doses of 20% and 30% LD50 both 
significantly attenuated intraoperative hemorrhage compared to that of SBI animals given saline only (vehicle); 
however, the reduction in hemorrhage plateaued at the 20% LD50 level.
Cv-PC Reduces Postoperative Hematoma In Vivo. Next, the effect of Cv-PC on the development of 
postoperative hematoma in the brain parenchyma was examined. Assessed at 24 h after SBI surgery, the postop-
erative hematoma demonstrated a dose-dependent decrease in volume by 48.7% to 64.9% for Cv-PC, which was 
significantly decreased for all doses compared to that of SBI animals receiving vehicle preconditioning (Fig. 1C). 
The postoperative hematoma volume in vehicle preconditioned animals was 22.5 ± 1.6 μ L, and that of Cv-PC 
animals was 11.3 ± 1.2 μ L, 8.0 ± 0.7 μ L, and 7.9 ± 0.5 μ L in the 10%, 20%, and 30% LD50 doses, respectively.
Cv-PC Increases Plasma Fibrinogen and Plasma Fibrin Split Products in Rats. To assess the hema-
tologic effects of Cv-PC, coagulation parameters were measured following administration of vehicle or Cv-PC 
in Naïve rats at 24 h following the third dose of C. atrox venom (corresponding to the intended surgery time) or 
at 6 h post-surgery in animals that received SBI (Fig. 2A). Naïve rats that received Cv-PC showed significantly 
increased plasma fibrinogen at time of surgery. Plasma fibrinogen was also elevated in rats at 6 h after SBI (Fig. 2B 
and Table 1). By the time of surgery, Cv-PC raised plasma fibrinogen by an average of 78.4 mg/dL—a 31.6% 
increase in concentration. At 6 h post-SBI, the fibrinogen remained higher in the Cv-PC animals than that of 
Vehicle preconditioned animals. Fibrin split products were only detected in the plasma of Cv-PC animals.
Prothrombin Time, International Normalized Ratio, Partial Thromboplastin Time, D-Dimer, 
and Soluble Fibrin Remain Normal After Cv-PC in Rats. To assess Cv-PC’s potential for inducing 
coagulopathic events we measured prothrombin time, international normalized ratio, partial thromboplastin 
time, D-Dimer, and soluble fibrin. No clinically significant changes in these parameters were observed following 
Cv-PC in Naïve animals or rats after SBI with the exception of elevated soluble fibrin in the SBI + Cv-PC animals 
(Table 1).
Figure 2. Cv-PC increases plasma fibrinogen and generates fibrin split products. (A) Schematic timeline 
of treatments and outcomes; rats received three subcutaneous injections of vehicle (normal saline), Cv-PC 
doses (20% of the LD50 dose), or Cv-PC doses incubated with matrix metalloproteinase inhibitor (MMP-I; 
with equal concentrations of Marimastat and AG-3340 to C. atrox venom) at 72 h, 48 h, 24 h prior to blood 
draw by cardiac puncture or surgery; animals undergoing surgery received blood draws at 6 h post-surgery. 
(B) Cv-PC significantly increased plasma fibrinogen at the time of surgery and at 6 h post-surgery; matrix 
metalloproteinase inhibition suppressed Cv-PC-induced increase in fibrinogen. (C) Fibrin split products were 
only detectable in the plasma of Cv-PC animals. Matrix metalloproteinase inhibition suppressed formation 
of fibrin split products by Cv-PC. #p < 0.05 vs Vehicle, †p < 0.05 vs Vehicle + SBI, ‡p < 0.05 vs Cv-PC. Data are 
shown as mean ± SEM, n = 8–12 all groups. 1-way ANOVA, with Tukey’s comparisons, was used to determine 
differences.
www.nature.com/scientificreports/
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Preconditioning with Several C. atrox Fractions Reduces Intraoperative Hemorrhage and 
Postoperative Hematoma Volumes in the SBI Rat Model. Whole C. atrox venom and its fractions 
from gel filtration separation (Fig. 3B) were separated by reversed-phase HPLC (Fig. 3A), and fraction compo-
nents of all substantial peaks were identified by LC-MS. A significant portion of the crude venom from C. atrox 
Naïve SBI
Vehicle Cv-PC Cv-PC + MMP-I Vehicle Cv-PC
n = 12 10 10 10 8
Fibrinogen (mg/mL) 248.9 ± 4.9 327.6 ± 9.1* 271.0 ± 10.6 273.2 ± 7.6 356.9 ± 17.6*
Fibrin Spilt Products (μ g/mL) 0.0 ± 0.0 26.0 ± 9.6* 1.0 ± 1.0 0.0 ± 0.0 10.0 ± 0.0*
Prothrombin Time (s) 10.67 ± 0.05 10.52 ± 0.05 10.34 ± 0.08 10.25 ± 0.10 10.04 ± 0.07
International Normalized Ratio 0.97 ± 0.01 0.92 ± 0.01 0.93 ± 0.01 0.91 ± 0.01 0.90 ± 0.00
Partial Thromboplastin Time (s) 15.07 ± 0.15 14.76 ± 0.04 15.32 ± 0.38 15.16 ± 0.12 14.83 ± 0.04
D-Dimer (μ g/mL) 0.03 ± 0.01 0.00 ± 0.00 0.04 ± 0.02 0.01 ± 0.01 0.06 ± 0.01
Soluble Fibrin (ng/mL) 41.8 ± 8.9 65.6 ± 8.1 48.2 ± 10.2 39.5 ± 6.7 80.8 ± 11.3*
Table 1.  Coagulation parameters after Crotalus atrox venom preconditioning. Data are shown as 
mean ± SEM. Cv-PC, C. atrox venom preconditioning; MMP-I, matrix metalloproteinase inhibitor; SBI, 
surgical brain injury. *p < 0.05 vs Vehicle.
Figure 3. Reversed-phase HPLC and gel filtration chromatographs of C. atrox venom. (A) Reversed-Phase 
HPLC of crude C. atrox venom and C. atrox venom fractions (Fr) collected from gel filtration chromatography; 
absorbance at 214 nm. Shaded regions represent snake venom metalloproteinase components identified by 
MALDI mass spectrometry. (B) Gel Filtration Chromatograph of C. atrox venom fractionation. Collected 
fractions are labeled in red numbers.
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was identified as snake venom metalloproteinases (grey shading on Fig. 3A, also see Supplemental Fig. S1 and 
Supplemental Table S1). The peaks which correspond to snake venom metalloproteinases in each HPLC fraction 
is displayed with the grey shading (Fig. 3A). The gel filtration fractions 2–5 had the greatest concentrations of the 
snake venom metalloproteinases in the C. atrox venom.
To identify which protein(s) may be responsible for Cv-PC with C. atrox venom, the individual gel filtration 
C. atrox venom fractions 1, 2, 3, 4, 5 and pooled fractions 6–8 were used for separate Cv-PC regimens. Cv-PC with 
fractions 2, 3, 4, and 5 improved intraoperative hemorrhage volumes (Fig. 4A), while all fractions had marked 
reductions of the postoperative hematoma (Fig. 4B).
Matrix Metalloproteinase Inhibition Blocks Cv-PC Effects on Hemorrhage Volumes, Plasma 
Fibrinogen and Fibrin Split Products in the Rat SBI Model. To evaluate the role of snake venom 
metalloproteinases in Cv-PC against SBI, two matrix metalloproteinase inhibitors were coadministered with 
C. atrox venom for each injection during Cv-PC. The concomitant administration of matrix metalloproteinase 
inhibitors abolished the increase in plasma fibrinogen by Cv-PC (Fig. 2B and Table 1) to levels similar to that 
of Vehicle preconditioned animals for both the naïve and SBI groups. Additionally, Cv-PC administered with 
matrix metalloproteinase inhibitors significantly diminished the generation of fibrin split products (Fig. 2C and 
Table 1). Furthermore, snake venom metalloproteinase inhibition by matrix metalloproteinase inhibitors had 
similar intraoperative hemorrhage and postoperative hematoma volumes to those of vehicle preconditioning 
animals; abolishing the protective effects of Cv-PC (Fig. 4B and C).
Direct Fibrinogen Administration Reduces Intraoperative Hemorrhage and Postoperative 
Hematoma Volumes in the Rat SBI Model. To determine the effect of direct fibrinogen administration 
on SBI pathophysiology, 15 mg/1.5 mL of fibrinogen was administered 15 min prior to induction of surgery. In 
Figure 4. Cv-PC intraoperative hemorrhage and postoperative hematoma in SBI. (A) Schematic timeline of 
treatments and outcomes; rats received three subcutaneous doses of vehicle (normal saline), Cv-PC (20% of the 
LD50 dose), Cv-PC doses incubated with matrix metalloproteinase inhibitor (MMP-I; with equal concentrations 
of Marimastat and AG-3340 to C. atrox venom), or fractions (Fr) of C. atrox venom at 72 h, 48 h, 24 h prior to 
surgery. Sham animals received craniotomy only. Fibrinogen-treated animals received one dose of fibrinogen 
(Fb, 15 mg/1.5 mL) 15 min before surgery. Routes of dose administration were either subcutaneous (sc) or 
intravenous (iv). Intraoperative hemorrhage volume was collected throughout surgery and postoperative 
hematoma was collected at 24 h post-surgery. (B) Intraoperative hemorrhage volume was significantly reduced 
by Cv-PC (20% LD50) and Cv-PC by Fr 2, 3, and 4. Matrix metalloproteinase inhibition during Cv-PC reversed 
the effect. Direct administration of fibrinogen reduced intraoperative hemorrhage. (C) Postoperative hematoma 
volume was significantly decreased by Cv-PC (20% LD50) and Cv-PC by all fractions. Matrix metalloproteinase 
inhibition during Cv-PC reversed the effect. Direct administration of fibrinogen reduced the development 
of postoperative hematoma. *p < 0.05 vs Sham, #p < 0.05 vs Vehicle, ‡p < 0.05 vs Cv-PC (20% LD50). Data are 
shown as mean ± SEM, n = 5–6 all groups. 1-way ANOVA, with Tukey’s comparisons, was used to determine 
differences.
www.nature.com/scientificreports/
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fibrinogen-treated animals, a reduction of intraoperative hemorrhage (Fig. 4B) and postoperative hematoma 
volumes (Fig. 4C) were observed comparable to those of Cv-PC animals.
C. atrox Venom Causes Hemostatic Changes in Human Whole Blood. To begin assessing the clin-
ical feasibility of Cv-PC, the direct effects of C. atrox venom on human whole blood was evaluated for clotting, 
sticking, and clumping parameters (Fig. 5). No change in any of these measures was found for saline; however, 
C. atrox venom has a dramatic effect on human whole blood. Initially, C. atrox venom caused a rapid decrease (for 
stick and clump times), which was then followed by an increase in all three parameters.
Discussion
Perioperative hemorrhage is a devastating complication in neurosurgery1,2, making optimization of hemostasis 
of the utmost importance. This study uses a novel preemptive approach for improving perioperative hemostasis 
by eliciting endogenous mechanisms using C. atrox venom preconditioning. Our hypothesis was that Cv-PC 
would attenuate the hemorrhage induced by SBI via an increase of endogenous fibrinogen production. First, we 
observed that Cv-PC reduces intraoperative blood loss and postoperative hematoma by more than 30% in the SBI 
rodent model. Second, while coagulation was improved by Cv-PC, coagulation parameters—prothrombin time, 
international normalized ratio, partial thromboplastin time, D-Dimer, and soluble fibrin—showed no indication 
that Cv-PC caused a thrombotic state. Third, our results point to snake venom metalloproteinases as the active 
component of C. atrox venom that cleaves fibrinogen into fibrin split products and imparts the protective effects 
of Cv-PC; and inhibition of snake venom metalloproteinases reversed the effects of Cv-PC. Finally, precondition-
ing with C. atrox venom fractions, which primarily contain snake venom metalloproteinases, retained the effects 
of Cv-PC by crude venom.
Given the ability of Crotalus venoms to generate fibrin split products without the initiation of clotting26,27, 
and the previously demonstrated induction by fibrin split products of hepatocyte fibrinogen production28–30, 
C. adamanteus, C. atrox, and C. viridis helleri venoms were considered for preconditioning. We elected to use 
C. atrox venom because it has been demonstrated to have strong fibrinolytic activity with no detectable fibrino-
gen clotting activity, whereas the other Crotalus venoms were measured to have some fibrinogen clotting activ-
ity31. To determine the optimal dose of venom that can elicit therapeutic benefit to animals subjected to SBI, a 
dose dependent study was conducted in which we administered three daily doses of C. atrox venom (10%, 20%, 
and 30% of the LD50; 1.85 mg/kg, 3.7 mg/kg, and 5.55 mg/kg, respectively) with the last dose 24 h prior to sur-
gery. The results of the dose dependent study suggest that the effectiveness of Cv-PC for reducing intraoperative 
Figure 5. Effects of C. atrox venom on human whole blood in vitro. Minimal stimulation clotting/platelet 
testing imitates in vivo clotting on a sample of whole blood and measures three parameters—clot, clump, and 
stick times. Clot time correlates with fibrinogen, intrinsic/extrinsic pathway function, whereas clump and stick 
times correlate well with platelet function. C. atrox venom causes an increase in (A) clot time, (B) stick time, 
and (C) clump time. Data are shown as mean ± SEM, n = 3 all groups.
www.nature.com/scientificreports/
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hemorrhage and postoperative hematoma volumes plateaus at the 20% LD50 dose. Additionally, these data suggest 
that Cv-PC is a viable treatment to improve hemostasis in the SBI neurosurgical model.
Prothrombin time, international normalized ratio, and partial thromboplastin time are routinely assessed 
to evaluate the extrinsic and intrinsic pathways of the coagulation cascade. Increased international normalized 
ratio or prolongation of prothrombin time or partial thromboplastin time is suggestive of bleeding diathesis. 
Shortened partial thromboplastin time may be associated with increased risk of venous thromboembolism32. 
D-Dimer and soluble fibrin levels are used to screen for disseminated intravascular coagulation, which is charac-
terized by systemic activation of blood coagulation and subsequent formation of microvascular thrombi that may 
ultimately lead to severe bleeding by consumptive depletion of coagulation factors and/or platelets33. The findings 
that Cv-PC had no clinically significant effect on any of these parameters supports previous findings that C. atrox 
venom has limited clotting activity31.
Initially, C. atrox venom was fractionated by reverse-phase chromatography, which may denature proteins, 
and is therefore unsuitable for assays of biological activity; thus, gel filtration chromatography, which preserves 
protein activity but achieves much lower resolution in protein separation than reversed-phase chromatography 
was utilized to obtain 9 fractions. These fractions were administered intravenously to assure intravascular expo-
sure to the C. atrox venom components. In both intraoperative and postoperative hemorrhage volumes, fractions 
2, 3, and 4, which contain primarily snake venom metalloproteinases (Fig. 3), provided improved hemostasis 
most consistently. The whole venom profile was dominated by a large peak complex eluting between 230 and 
250 min, which aligned with major peaks in Gel-Filtration fractions 2–4 (Fig. 3A) MALDI protein identification 
indicated these peaks were composed entirely of snake venom metalloproteinases. Metalloproteinase fragments 
were also identified in several smaller peaks eluting between 215 and 245 min, which corresponded to peaks in 
Gel-Filtration fraction 5 and may explain the lesser Cv-PC activity also exhibited by this fraction.
To further elucidate snake venom metalloproteinases as the primary protein responsible for increased home-
ostasis during SBI, we evaluated the effects of blocking snake venom metalloproteinases during Cv-PC. Since 
specific inhibitors of snake venom metalloproteinases are not available, we elected to use commercially available 
matrix metalloproteinase inhibitors, Marimastat and AG-3340, which have been previously described to block 
other snake venom metalloproteinases34. Our findings, that coadministration of matrix metalloproteinase inhib-
itors and C. atrox venom during preconditioning prevents Cv-PC benefits, suggest that snake venom metallopro-
teinases plays a crucial role in the generation of fibrin split products and fibrinogen, as well as in the improved 
hemostasis conferred by Cv-PC.
To determine if fibrinogen was the key mediator of Cv-PC effect after SBI, fibrinogen treatment was given 
15 minutes before SBI (15 mg/1.5 mL of fibrinogen). This dose was determined by computing the required 
amount of protein to raise plasma fibrinogen by approximately 75 mg/dL, given the estimated blood volume of 
the animals, as previously published35. Our results showed that this dose of fibrinogen, which correlates with the 
increase in fibrinogen concentration provided by Cv-PC, was capable of improving perioperative hemostasis.
Minimal stimulation clotting/platelet testing, which imitates in vivo clotting on a sample of whole blood, 
measures three parameters—clot, clump, and stick times. Clot time correlates with fibrinogen, intrinsic/extrinsic 
pathway function, whereas clump and stick times correlate well with platelet function. The increase in all three 
parameters by C. atrox venom demonstrates impaired clotting function. The prolonged clot time likely repre-
sents a depletion of fibrinogen by snake venom metalloproteinase cleavage. The prolonged clump and stick times 
indicate decreased platelet function, which likely results from fibrinogen depletion, as platelets are supported by 
fibrinogen to mediate adhesion and aggregation36–38.
Our findings are congruent with the growing body of literature that emphasizes plasma fibrinogen level as a 
potential modifiable risk factor for perioperative hemorrhage16–21. These studies indicate that lower fibrinogen, 
even within normal limits, are correlated with increased bleeding and that higher levels of fibrinogen are asso-
ciated with better outcomes. Fibrinogen is fundamental to effective clot formation. It circulates at the highest 
concentration of all the coagulation factors and is the first coagulation factor to drop to critically low levels during 
major hemorrhage39. Dilutional deficiency of fibrinogen develops earlier than any other hemostatic abnormal-
ity when plasma-poor red blood cell preparations are used to replace blood loss40. Yet in current practice, the 
options for increasing plasma fibrinogen are limited to transfusions of fibrinogen-containing preparations like 
fresh frozen plasma, cryoprecipitate, and fibrinogen concentrate. Fresh frozen plasma varies in fibrinogen con-
centration as it is collected from donors. The concentration of fibrinogen in fresh frozen plasma reportedly ranges 
between 100–300 mg/dL41. Because of these concentrations, large volumes of fresh frozen plasma are necessary 
for even modest increases in plasma fibrinogen. Cryoprecipitate, obtained by concentrating fresh frozen plasma, 
has about 200 mg of fibrinogen per unit at a concentration of about 550 mg/dL42. Fibrinogen concentrate, man-
ufactured from human plasma and available as a pasteurized, lyophilized powder, is given at a concentration of 
2000 mg/dL43. A previous study determined that in order to raise plasma fibrinogen levels from 150 mg/dL to 
170 mg/dL, requires 14 units of fresh frozen plasma, 8 units of cryoprecipitate, or 2 units of fibrinogen concentrate 
making fluid overload an important consideration in fibrinogen supplementation. In addition, these transfu-
sions are not without risk; they are associated with complications that include allergic reaction, infections, and 
transfusion-related acute lung injury22,23.
An estimated 31% of elective neurosurgeries require blood transfusions44. A preventive therapy that reduces 
perioperative hemorrhage would decrease the need for blood transfusions, ultimately cutting perioperative costs; 
up to $6.03 million is spent on blood and transfusion-related care for surgical patients annually per hospital45. 
While our study focused on Cv-PC in the SBI model, the implications of our results extend beyond the field of 
neurosurgery. Cv-PC could also be applied to elective surgeries in other fields, as perioperative hemorrhage is the 
bane of surgeons in every specialty. Over 200 million major elective surgeries are performed worldwide per year46.
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Limitations and Future Studies. There are several limitations of this study. First, the C. atrox venom 
preconditioning regimen was arbitrarily selected. Herein, we used three days of single injections to precondition 
against SBI. Future studies will need to evaluate additional preconditioning regimens to determine the opti-
mal dosing required to promote a significant rise in plasma fibrinogen levels. Second, C. atrox venom contains 
numerous proteins which are known to have hemostatic properties, including anti- and pro-coagulation. Here, 
we used gel filtration followed by HPLC to fractionate the crude C. atrox venom. However, the vast number of 
proteins in the crude venom required us to utilize pooled venom fractions (from gel filtration) to make the study 
manageable. Future studies will investigate the HPLC fractions of the gel filtration fractions which were capable of 
preconditioning against SBI and to establish a mechanism of protection (i.e. further fractionation of gel filtration 
fractions 2–5). Third, while our study demonstrated that Cv-PC did not result in coagulation parameters indic-
ative of a thrombotic state, more studies are needed to assess whether the Cv-PC increases the risk of pathologic 
thrombotic events. Finally, additional studies are needed to assess the translational feasibility of Cv-PC and its 
safety.
Methods
Animal Experiments. All animal experiments were approved by the Institutional Animal Care and Use 
Committee at Loma Linda University and conducted in compliance with the NIH Guidelines for the Use of 
Animals in Neuroscience Research. Animals were housed in cages on a constant 12-h light/dark cycle in a con-
trolled temperature room and were given food and water ad libitum. One hundred twenty-one male Sprague 
Dawley rats (280–330 g) were used in this study.
Groups. The effects of Cv-PC on coagulation parameters as a therapy for SBI was investigated using naïve 
and SBI rats. Naïve animals were preconditioned with either the vehicle (normal saline), C. artrox venom, or 
C. atrox venom with matrix metalloproteinase inhibitors. SBI animals were divided in four groups: sham, vehicle 
preconditioning, Cv-PC, and fibrinogen treatment.
Interventions – Naïve Animals. Vehicle preconditioned and Cv-PC animals received a single subcutane-
ous dose of C. atrox venom (or normal saline for the vehicle group) each day for three consecutive days before 
sacrifice (with the final dose 24 hours before sacrifice). A 20% LD50 dose of C. atrox venom was used (3.7 mg/kg). 
In Cv-PC + matrix metalloproteinase inhibitor animals, C. atrox venom (20% LD50) was incubated with 
Marimastat (3.7 mg/kg, Sigma) and AG-3340 (3.7 mg/kg, Sigma) for 30 min at 37 °C prior to subcutaneous injec-
tion34,47. The mixture of the crude venom and matrix metalloproteinase inhibitors was administered each day for 
three consecutive days before sacrifice.
Interventions – SBI Animals. Vehicle preconditioned and Cv-PC animals received a single subcutaneous 
dose of C. atrox venom (or normal saline) each day for three consecutive days before SBI (with the final dose 
24 hours before SBI). In the dose study (Fig. 1), C. atrox venom was administered at 10%, 20%, and 30% of the 
LD50 (1.85 mg/kg, 3.7 mg/kg, and 5.55 mg/kg, respectively). For the remainder of the experiments, the 20% LD50 
dose of C. atrox venom was used; for Cv-PC conducted with Cv fractions, the same 3.7 mg/kg dosing was applied. 
Fibrinogen-treated animals received one dose of fibrinogen (1.5 mL, 10 mg/mL, Sigma) 15 min before SBI.
To identify the venom protein(s) responsible for the hemostatic effects, crude C. atrox venom was fractionated 
(as described below). Each fraction of the C. atrox venom was reconstituted in normal saline. The dose of each 
fraction was equivalent to its mass concentration of the crude venom (at 20% LD50). Preconditioning for each 
C. atrox venom fraction was performed via single IV injections each day for three consecutive days before SBI.
Surgical Brain Injury Model. Rats underwent craniotomy and a partial right frontal lobe resection 1 mm 
above the horizontal line from bregma and 2 mm to the right of the vertical line from bregma down to the skull 
base as previously described4,5. After bleeding stopped, animals were sutured and allowed to recover. Sham ani-
mals underwent all surgical procedures with the exception of brain resection.
Spectrophotometric Assay of Hemoglobin Volume. At 24 h after SBI, the animals were placed under 
deep anesthesia and transcardially perfused with 0.1 M PBS until the outflowing fluid from the right atrium 
became colorless. The brain was removed and dissected into left and right hemispheres. Hematoma volume was 
quantified by spectrophotometric assay of brain hemoglobin content as described previously48. A standard curve 
was obtained by adding incremental volumes of homologous blood to perfused brain tissue of naïve animals. 
The hemispheric samples were then homogenized and sonicated in distilled water followed by a 30-min cen-
trifugation (13,000 g at 4 °C); Drabkin reagent (1.6 mL; Sigma) was added to 0.4 mL supernatant aliquots and 
optical density was measured at 540 nm via a spectrophotometer (Spectronix 3000; Milton-Roy). Hemoglobin 
measurements were compared with the standard curve to obtain hemorrhage volume expressed as μ L of blood 
per ipsilateral hemisphere.
Intraoperative hemorrhage volume was collected by suction throughout surgery and was added to packing 
material used for hemostasis during the procedure; distilled water was added bringing the volume to 50 mL for 
each collected hemorrhage sample. A standard curve was obtained by adding incremental volumes of homolo-
gous blood to distilled water to create solutions of 50 mL total volume. Samples were homogenized, sonicated, and 
prepared for spectrophotometric assay as described above. Testing was done in duplicate.
Blood Draws. 6 h after SBI, animals were anesthetized with isoflurane and blood was collected by cardiac 
puncture using an 18-gauge needle; the first few drops of blood were discarded to eliminate tissue factor from the 
blood draw. Collected blood rapidly transferred to the appropriate collection tubes, gently mixed by ten inver-
sions, and delivered to the appropriate laboratories for subsequent testing.
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Specimens destined for soluble fibrin, prothrombin time, international normalized ratio, partial thrombo-
plastin time, fibrinogen and D-Dimer testing were anticoagulated in a mixing ratio of one part citrate to nine 
parts blood using Greiner Bio-One Vacuette® tubes (Part No. 454334) containing 3.2% (0.109 M) Sodium Citrate 
Solution. Specimens for Fibrin Split Product testing were added to Thrombo-Wellcotest™ Collection Tubes 
(Part No. R30853001) containing soy bean trypsin inhibitor (approximately 3600 NF units/tube) and C. atrox 
venom (> 10 μ g/tube) for the collection of each 2 mL of whole blood.
Previous studies have established normal ranges in rats using human test methods33.
Soluble Fibrin Analysis. All samples were maintained at 37 °C from draw through testing. The testing was 
as described by Hay et. al., but modified slightly since the appearance of endpoints in rat blood were somewhat 
atypical as compared to human endpoints49. The modification (reading endpoints using 90 μ L plasma rather than 
the usual 150 μ L whole blood) clarified the endpoints and allowed for comparison between rats and treatment 
groups. However, the results cannot be compared to usual human values.
Prothrombin Time, International Normalized Ratio, Partial Thromboplastin Time, and 
Fibrinogen Analysis. Blood was centrifuged at 7200 RPM (4440 × g) for 2 min using the STATSpin Express 
3 to obtain plasma for testing. Testing was performed using a BCS® XP System (Siemens Healthcare, Munich, 
Germany). The prothrombin time and international normalized ratio were performed using Dade® Innovin® 
reagent. The partial thromboplastin time was performed using Dade® Actin® FSL reagent and 0.025 M CaCl2. 
Fibrinogen assays were performed using Dade® Thrombin Reagent, Dade® Fibrinogen Standard and Dade® 
Owren’s Veronal Buffer.
D-Dimer Analysis. Blood was centrifuged at 7200 RPM (4440 × g) for 2 min using the STATSpin Express 3 
to obtain plasma for testing. Testing was performed using the Cobas® 8000 modular analyzer (Roche Diagnostics, 
Indianapolis, IN). The method is based on latex particles coated with monoclonal anti-human D-Dimer anti-
bodies (mouse) to which addition of a sample containing D-Dimer increases turbidity leading to changes in 
absorbance over time.
Fibrin Split Products Analysis. Blood was centrifuged at 7200 RPM (4440 × g) for 2 min using the 
STATSpin Express 3 to obtain serum for testing. Testing was performed using the Thrombo-Wellcotest™ Rapid 
Latex FDP Assay. The kit test utilizes latex particles, which have been coated with rabbit antibodies to fibrin frag-
ments. The approximate concentration is determined from agglutination observed on serial specimen dilutions.
HPLC of C. atrox Venom. Lyophilized crude venom was diluted to a concentration of 6 mg/mL in Buffer 
A (0.065% TFA, 2% acetonitrile in Nanopure water) and centrifuged at 15,000 g for 10 min. 100 μ L of the super-
natant was fractionated on an ÄKTAmicro high-pressure liquid chromatography system (GE Healthcare Life 
Sciences, Piscataway, NJ, USA) fitted with two reversed-phase (RP) columns (SOURCE 5RPC ST polystyrene/
divinylbenzene, 4.6 150 mm; GE Healthcare) run in series at a flow rate of 0.5 mL/min, using a linear gradient 
of 0–100% Buffer B (0.05% TFA, 80% acetonitrile in Nanopure water) over 40 column volumes. Protein elution 
was monitored at 214 nm using Unicorn 5.0 (GE Healthcare Lifesciences) software, and fractions were collected 
manually.
Protein Identification. Each Reversed-Phase fraction was subjected to reduction and alkylation using dith-
iothreitol and iodoacetamide, respectively. Proteins were then digested with proteomics-grade porcine pancreatic 
trypsin (Sigma-Aldrich, St. Louis, MO). Samples were desalted using C18 ZipTips (EMD Millipore, Billerica, MA) 
according to the manufacturer’s protocol and submitted the samples to Shimadzu Scientific Instruments, Inc. 
(Columbia, MD) for peptide identification by Matrix-Assisted Laser Desorption/Ionization (MALDI). Because 
Reversed-Phase HPLC may denature proteins, these fractions were not used in the physiological activity assays. 
Instead, venom for Cv-PC use was fractionated via Gel Filtration chromatography using a Superdex gel filtra-
tion column (HiLoad 16-/60 Superdex 75PG, 17–1068–02, GE Healthcare) on an Amersham Biosciences ÄKTA 
FPLC (18–1900–26, GE Healthcare). Crude venom (4 mg/mL in 0.15 M ammonium bicarbonate) was injected 
into the column (500 mL sample) and separated in 0.15 M ammonium bicarbonate at a flowrate of 1 mL/min. 
Individual fractions were collected manually at the local minimums of each peak (based on absorbance at 
214 nm). All collected fractions were lyophilized and stored at − 20 °C until use. The protein concentration of each 
reconstituted fraction was measured using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific). 
Although Gel Filtration chromatography preserves protein activity, it fails to achieve the level of protein sep-
aration required for mass spectrometry. Therefore, to determine which venom components may explain the 
observed Cv-PC activity, each Gel Filtration fraction was subjected to Reversed-Phase HPLC, and the resulting 
partial venom profiles aligned against the whole venom Reversed-Phase chromatogram whose peaks were iden-
tified by mass spectrometry (Fig. 3A).
Minimal Stimulation In Vitro Clotting/Platelet Testing. Consenting normal adults donated 5 mL of 
blood for each agent to be tested. Blood was drawn into citrated syringes (1 part citrate + 9 parts blood) and 
mixed gently, then all air was expressed, and a parafilm seal was placed over the luer tip. Syringes were maintained 
horizontally at 37 °C for approximately 50–60 min, allowing endothelial inhibitors to dissipate and platelet func-
tion to reach a stable phase. During this stable phase, multiple tests could be performed and the results compared.
Baseline platelet testing was done in duplicate at 37 °C as follows. Pre-warmed reaction tubes containing 1 mg 
Celite 270 (Manville Products, Denver, CO), 450 μ L of 0.0055 M isotonic CaCl2 and 25–35 solid glass beads, 
0.5 mm (#030001, Propper Manuf Co, NY) were pre-mixed. To this 3 drops (~150 μ L) of well-mixed blood were 
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added and time to completion of the clumping, sticking and clotting visual endpoints was measured on the 
Hemostasis Mechanism Analyzer (Boehringer Laboratories, Norristown, PA).
When done with baseline testing, the blood level in each syringe was adjusted to exactly 3 mL in preparation 
for testing of the various venom concentrations. After remixing, 10 μ L of the venom was carefully added midway 
in the column of 3 mL whole blood using a Drummond pipette. After 30 s, the sample was remixed and testing 
was performed as described above. Testing was repeated periodically over ~20 min to monitor changes in platelet 
and clotting function after exposure to the venom.
Statistical Analysis. All values are mean ± SEM. GraphPad Prism software was used for statistical analysis. 
We compared treatment groups for each dependent measure using a one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparisons. A p value < 0.05 was considered significant.
Study Approval. All animal husbandry and procedures were approved by the Institutional Animal Care and 
Use Committee. The study protocol was approved by the Institutional Review Board at Loma Linda University.
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